K
Ketki Bhise
Researcher at Eugene Applebaum College of Pharmacy and Health Sciences
Publications - 20
Citations - 1752
Ketki Bhise is an academic researcher from Eugene Applebaum College of Pharmacy and Health Sciences. The author has contributed to research in topics: Cancer & Tumor microenvironment. The author has an hindex of 9, co-authored 20 publications receiving 1191 citations. Previous affiliations of Ketki Bhise include Wayne State University & Institute of Chemical Technology.
Papers
More filters
Journal ArticleDOI
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome.
Hashem O. Alsaab,Hashem O. Alsaab,Samaresh Sau,Rami Alzhrani,Rami Alzhrani,Katyayani Tatiparti,Ketki Bhise,Sushil K. Kashaw,Sushil K. Kashaw,Arun K. Iyer,Arun K. Iyer +10 more
TL;DR: The current landscape of the PD-1/PD-L1 mechanistic role in tumor immune evasion and therapeutic outcome for cancer treatment is reviewed and the current progress in clinical trials, combination of drug therapy with immunotherapy, safety, and future of check point inhibitors for multiple types of cancer are reviewed.
Journal ArticleDOI
Recent advances in hyaluronic acid-decorated nanocarriers for targeted cancer therapy.
Jennifer M. Wickens,Hashem O. Alsaab,Prashant Kesharwani,Ketki Bhise,Mohd Cairul Iqbal Mohd Amin,Rakesh K. Tekade,Umesh Gupta,Arun K. Iyer,Arun K. Iyer +8 more
TL;DR: In vitro and in vivo experiments have repeatedly indicated HA-based nanocarriers to be a target-specific drug and gene delivery platform with great promise for future applications in clinical cancer therapy.
Journal ArticleDOI
Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment.
Samaresh Sau,Hashem O. Alsaab,Ketki Bhise,Rami Alzhrani,Ghazal Nabil,Arun K. Iyer,Arun K. Iyer +6 more
TL;DR: The role of multifunctional polymeric, lipid, metallic and cell based nanoparticles for improving current immunotherapy and the function of host immune stimulatory signals and tumor immunotherapies can be improved by repurposing of nanomedicine platform are summarized.
Journal ArticleDOI
Nanostructured lipid carriers employing polyphenols as promising anticancer agents: Quality by design (QbD) approach.
TL;DR: The science behind development of NLCs and role of polyphenols as promising anticancer agents are reviewed and Principles of Quality by Design (QbD) have also been explained which are used in formulation-development of many nanoparticles, including N LCs, as reported in literature.
Journal ArticleDOI
Nano-engineered delivery systems for cancer imaging and therapy: Recent advances, future direction and patent evaluation.
TL;DR: This review has focused on various types of theranostic polymer and metal nanoparticles for their role in cancer therapy and imaging concerning their limitation, future application such as dendritic cell cancer vaccination, gene delivery, T-cell activation and immune modulation.